Five-year-old Leap Therapeutics Inc. stands to become a public company as the surviving entity in its merger with the Israeli biopharma, Macrocure Ltd., which will operate as a wholly owned subsidiary. Leap, of Cambridge, Mass., was founded in 2011 and raised $30.5 million the same year in a round led by Healthcare Ventures and its funds, according to SEC filings. Earlier this year, Healthcare Ventures was said to have combined its portfolio companies Healthcare Pharmaceuticals Inc. and GITR Inc. into Leap.